High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma

Erik Björck, Sara Ek, Ola Landgren, Mats Jerkeman, Mats Ehinger, Magnus Björkholm, Carl A.K. Borrebaeck, Anna Porwit-MacDonald, Magnus Nordenskjöld

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Substantial research has been dedicated to the study of the relationship between genetic mechanisms regulating cell functions in tumors and how those tumors respond to various treatment regimens. Because these mechanisms are still not well understood, we have chosen to study the genetic makeup of 57 tumor samples from patients with follicular lymphoma (FL). Our goal was to develop a prognostic tool, which can be used as an aid in determining FL patients with tumors genetically predisposed to a successful treatment with the CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) regimen. To select relevant genes, high-density oligonucleotide arrays were used. There were 14 genes highly expressed in FL patients that responded well to CHOP chemotherapy, and 11 of these were involved in G2/M transition of the cell cycle, in mitosis, or in DNA modulation. A high expression of CCNB1 (cyclin B1), CDC2, CDKN3A, CKS1B, ANP32E, and KIAA0101, but not of the proliferation-related antigen KI-67, was associated with better survival rate in a univariate analysis. CCNB1 expression had an independent prognostic value when included in a multivariate analysis together with the 5 parameters of the follicular lymphoma international prognostic index.

Original languageEnglish (US)
Pages (from-to)2908-2915
Number of pages8
JournalBlood
Volume105
Issue number7
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma'. Together they form a unique fingerprint.

Cite this